2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3479 TP53-region loss of heterozygosity identifies occult multi-hit disease and refines prognosis in TP53-mutated AML and MDS

Ruowen Wei, PhD, Yeqian Zhao2, Xin Ke3, Minli Hu4, Chuanhe Jiang5, Panruo Jiang6, Yamin Fan7, Jimin Shi8, Yi Luo9, Jian Yu10, Lizhen Liu11, Xiaoyu Lai12, Huarui Fu13, Yishan Ye, MD14, Congxiao Zhang15, Yi Yu16, Fei Gao17, Lixia Zhu18, Zhong Zheng Zheng, N/A19, Li Yu20, Shanshan Pei, PhD21, Wei Shi22, Jiexian Ma23, Gongqiang Wu24, Qunyi Guo25, Xiaoxia Hu, MD26, Fuming Zi27, He Huang, MD, PhD28, Yanmin Zhao, MD29
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
4 Department of Hematology, Taizhou Hospital of Zhejiang Province, Zhejiang University, Taizhou, China
5 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Jinhua, China
7 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
9 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
11 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
12 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
13 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
14 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
15 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
16 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
17 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
18 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
19 Shanghai Dishuo Beken Biotechnology Co., Ltd., Shanghai, China
20 Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
21 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
22 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
23 Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China
24 Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Jinhua, China
25 Department of Hematology, Taizhou Hospital of Zhejiang Province, Zhejiang University, Taizhou, China
26 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
27 Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
28 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
29 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background: Accurate assignment of TP53 allelic state is central to disease classification and risk stratification in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS). However, conventional criteria based on mutation number, cytogenetics, and variant allele frequency (VAF) may fail to identify TP53-region loss of heterozygosity (LOH), particularly copy-neutral LOH (CN-LOH), leaving clinically high-risk multi-hit disease unrecognized. We evaluated whether direct assessment of TP53-region LOH/CN-LOH could improve risk classification and prognostic stratification.

Methods: This retrospective study included 228 patients with TP53-mutated AML or MDS from 7 centers. TP53-region LOH/CN-LOH was assessed using AIM-LOH, a targeted sequencing assay integrating TP53 mutation, regional copy-number, and allelic-imbalance analysis. Baseline multi-hit status was defined by ≥2 TP53 mutations, 1 TP53 mutation with chromosome 17/17p deletion, or 1 mutation with VAF >55%; all others were classified as single-hit. Patients initially classified as single-hit but found to harbor LOH/CN-LOH were reclassified as upgraded multi-hit. Whole-exome sequencing (WES) was used for orthogonal validation. Overall survival (OS) and progression-free survival (PFS) were evaluated using multivariable Cox models, with allogeneic hematopoietic cell transplantation (HCT) modeled as a time-dependent covariate.

Results: The cohort included 147 patients with MDS and 81 with AML. TP53-region LOH/CN-LOH was detected in 108 patients (47%), including 78 with CN-LOH and 30 with deletion-associated LOH, and classification was fully concordant with WES in 29 evaluated cases. Among 75 patients initially classified as single-hit, 24 (32%) were reclassified as upgraded multi-hit. Complex or monosomal karyotype (odds ratio [OR], 3.29; 95% confidence interval [CI], 1.56-7.26; P=0.002) and TP53 VAF >55% (OR, 15.23; 95% CI, 7.07-36.24; P<0.001) were independently associated with LOH/CN-LOH, whereas multiple TP53 mutations were inversely associated (OR, 0.35; 95% CI, 0.16-0.75; P=0.008).
The 1-year PFS rates were 57.5%, 20.9%, and 26.1% for single-hit, baseline multi-hit, and upgraded multi-hit patients, respectively; corresponding 1-year OS rates were 66.3%, 31.3%, and 47.1%. Upgraded multi-hit patients had outcomes comparable to baseline multi-hit patients and significantly inferior to patients remaining single-hit. This pattern was retained among patients managed without HCT. Among patients with multiple TP53 mutations, concurrent LOH/CN-LOH identified an especially adverse subgroup, with 1-year PFS of 6.0% versus 34.8% (P=0.027) and 1-year OS of 19.5% versus 44.3% (P=0.013) compared with those without LOH/CN-LOH. In multivariable analysis, LOH/CN-LOH independently predicted inferior OS (hazard ratio [HR], 1.56; 95% CI, 1.07-2.25; P=0.019), while integrated multi-hit status independently predicted inferior OS (HR, 2.03; 95% CI, 1.25-3.29; P=0.004) and PFS (HR, 1.98; 95% CI, 1.30-3.02; P=0.001). In the HCT population, there was no significant difference in survival between single-hit and multi-hit cases, suggesting that transplantation overcomes the adverse prognosis associated with multi-hit TP53.

Conclusions: Direct assessment of TP53-region LOH/CN-LOH reclassified nearly one-third of conventionally defined single-hit patients and identified a clinically occult high-risk population with outcomes resembling established multi-hit disease. Incorporating directly determined TP53 allelic state into routine clinical evaluation may reduce risk misclassification and improve prognostic assessment and treatment planning in TP53-mutated AML and MDS.

Ruowen Wei, PhD: No relevant conflicts of interest to declare.